MariMed AI Stock Analysis
Want to see MRMD full AI Analyst Report?
MariMed (MRMD) AI Stock Analysis
MariMed
(Other OTC:MRMD)
The overall score is constrained by a precarious financial position, marked by significant net losses and extreme leverage that create substantial risk. Positive operational developments from the earnings call, such as record revenue and improving cash flow, and moderately bullish technical momentum provide a counterbalance, but the weak balance sheet and negative valuation are the most significant factors weighing on the score.
MariMed (MRMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $28.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 759.15K
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- 0.38
- Revenue Growth
- 6.32%
- EPS Growth
- 16.34%
- Country
- US
- Employees
- 866
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
MariMed Business Overview & Revenue Model
Company Description
MariMed Inc. operates in the cannabis industry, specializing in the cultivation, production, and sale of both medicinal and adult-use cannabis items throughout the United States and internationally. The company's diverse product portfolio includes ca...
How the Company Makes Money
MariMed primarily makes money through the sale of regulated cannabis products via two main channels: (1) Retail sales through company-operated dispensaries, where revenue is generated from direct-to-consumer purchases of cannabis flower and manufactu...
MariMed Earnings Call Summary
The call was broadly positive, supported by record revenue, growth across wholesale and retail, stronger distribution, improving transactions and average order value, sequential EBITDA growth, positive operating cash flow and a stronger balance sheet. Management also highlighted brand momentum, licensing expansion and planned New York growth. The main concerns were year-over-year gross-margin and EBITDA declines, higher taxes and interest expense, the 280E burden, continued price compression, input-cost inflation, regulatory uncertainty and constraints on Maryland expansion.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management did not provide formal fourth-quarter guidance, but said New York remains on schedule to launch in the first half of 2027, with Q4 and into next year focused on leveraging brands, cash position and production capacity; it expects hemp to be a catalyst, especially in Illinois as the ban comes into effect, and said licensing, including New York, will bring margin expansion, while retail strategies are being doubled down on going into 2027. Maryland’s store count increased about 10% year-to-date to about 120 stores, with wholesale penetration above 90%, and the company said it is currently at about 75% penetration in its wholesale business and sells about 1/3 of its own products in its stores.
MariMed Financial Statement Overview
Summary
Financial health is under severe stress. While TTM free cash flow turned positive ($9.1M), the income statement shows a swing to a net loss of $15.5M with compressed gross margins (35.4%). The balance sheet is critically weak, with equity nearly wiped out ($6.9M) and a debt-to-equity ratio of 13.05, posing a solvency risk.
Income Statement
35NegativeBalance Sheet
20Very NegativeCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 167.28M | 159.83M | 157.96M | 148.60M | 134.01M | 121.46M |
| Gross Profit | 59.16M | 57.88M | 62.87M | 65.92M | 63.96M | 66.26M |
| EBITDA | 9.98M | 9.44M | 13.83M | 11.16M | 25.91M | 28.96M |
| Net Income | -15.51M | -14.48M | -12.16M | -16.03M | 13.47M | 7.22M |
Balance Sheet | ||||||
| Total Assets | 198.31M | 202.56M | 206.99M | 196.12M | 152.20M | 123.20M |
| Cash, Cash Equivalents and Short-Term Investments | 10.36M | 8.88M | 7.28M | 14.73M | 9.86M | 29.93M |
| Total Debt | 90.48M | 100.09M | 88.47M | 80.13M | 37.37M | 24.37M |
| Total Liabilities | 151.33M | 152.56M | 147.11M | 126.21M | 94.89M | 86.91M |
| Stockholders Equity | 41.97M | 51.87M | 61.63M | 71.56M | 58.82M | 37.86M |
Cash Flow | ||||||
| Free Cash Flow | 9.13M | 6.53M | -5.89M | -12.85M | -5.43M | 17.29M |
| Operating Cash Flow | 10.08M | 7.70M | 6.79M | 7.91M | 7.31M | 35.85M |
| Investing Cash Flow | -1.75M | -1.38M | -17.13M | -25.98M | -26.24M | -16.62M |
| Financing Cash Flow | -4.57M | -4.71M | 2.98M | 22.98M | -1.01M | 7.45M |
MariMed Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRMD, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 55.69 is Neutral, neither overbought nor oversold. The STOCH value of 85.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRMD.
MariMed Risk Analysis
MariMed disclosed 39 risk factors in its most recent earnings report. MariMed reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMariMed Peers Comparison
Overall Rating
- MRMD51Neutral
TLRY46Neutral
IXHL43Neutral
YCBD43Neutral
IMCC29Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MRMD | 51Neutral | $30.28M | -1.75 | -40.72% | ― | 6.32% | 16.34% |
| TLRY | 46Neutral | $367.99M | -1.74 | -10.30% | ― | 15.93% | 93.85% |
| IXHL | 43Neutral | $25.34M | -2.94 | -12.40% | ― | -100.00% | 96.25% |
| YCBD | 43Neutral | $4.40M | -1.22 | -34.25% | ― | 10.01% | 95.01% |
| IMCC | 29Underperform | $911.06K | -0.02 | 841.81% | ― | -11.91% | -285.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MRMD | Marimed | 0.07 | -0.01 | -12.50% | |
| YCBD | Cbdmd INc | 0.37 | -0.23 | -37.67% | |
| TLRY | Tilray | 2.43 | -7.87 | -76.41% | |
| IMCC | Im Cannabis Corp | 0.57 | -29.39 | -98.10% | |
| IXHL | Incannex Healthcare Limited Sponsored ADR | 1.97 | -8.21 | -80.65% |
MariMed Corporate Events
MariMed Shareholders Approve Discretionary Reverse Stock Split
NeutralOn October 28, 2026, MariMed stockholders overwhelmingly approved a proposed reverse stock split of the company’s common stock at a special meeting. The authorization gives the board discretion to implement the split at a ratio between one-for-fifty...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026